Alcolase
Copenhagen, DK · Founded 2021 · 9 employees on LinkedIn · 6 known investors
Find your way into Alcolase
212 people in our graph share verified history with the Alcolase team — schools, employers, funds. One of them is your warm intro.
Alcolase is a biotech company developing science-based solutions for people with alcohol intolerance, a genetic condition affecting hundreds of millions of people, particularly in East Asia. It focuses on enzyme-based products to help those who experience adverse reactions to alcohol.
Founders & leadership
Alcolase was founded in 2021 by Mikkel Precht.
Investors · 6
.jpeg){kind=logo}
Also in the syndicate · 1
Funding
SEC filings, press & company announcements- Undisclosed amountSeed RoundMay 2026
Ada Ventures (lead), Antler (lead), Delphinus Venture Capital (lead), Manigoff Invest (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Alcolase is a Copenhagen-based biotechnology company developing an orally administered enzyme supplement intended for people with alcohol intolerance, in particular those carrying an ALDH2 deficiency. The product is a liposomal enzyme system: three enzymes are encapsulated inside liposomes and delivered to the stomach when the supplement is taken before drinking, where they are designed to convert ethanol into byproducts before the alcohol is absorbed into the bloodstream.
The company frames its approach as working alongside the body's own alcohol metabolism, supporting the breakdown of both ethanol and acetaldehyde in the stomach rather than after systemic absorption. Alcolase describes the product as still in development and positions it as the first enzyme supplement created specifically for alcohol intolerance.
Business model
Consumer supplement product taken before drinking alcohol; the company is at the development stage and has not disclosed commercial terms.
▸Full profile — market position, technology, go-to-market, geography
Market position
Alcolase describes its product as the world's first enzyme supplement developed for alcohol intolerance and states that no effective solution currently exists on the market for the condition.
Technology
The core technology is a liposomal delivery system that encapsulates three enzymes so they can reach the stomach intact. Once delivered, the enzymes are intended to catalyse the conversion of ethanol into harmless byproducts in the stomach, ahead of absorption into the bloodstream, and to support the breakdown of acetaldehyde as part of the body's existing alcohol metabolism pathway.
Go-to-market
Consumers affected by alcohol intolerance, specifically the estimated 540 million people worldwide who carry an ALDH2 deficiency that can make drinking alcohol painful or potentially dangerous.
Geography
Headquartered in Copenhagen, Denmark, with Singapore and South Korea identified as initial target markets.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Alcolase went on to found or lead other companies.
In the news
▸Research sources · 1
primary sources listed
- Alcolasealcolase.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Alcolase do?
- Copenhagen-based biotech developing a liposomal enzyme supplement that breaks down alcohol in the stomach for people with alcohol intolerance.
- Who founded Alcolase?
- Alcolase was founded by Mikkel Precht in 2021.
- Who are Alcolase's investors?
- Alcolase's investors include Ada Ventures, Antler, Antler Australia, Elmehøj Ventures, Delphinus Venture Capital.
- Where is Alcolase headquartered?
- Alcolase is headquartered in Copenhagen, DK.